Fresenius Kabi’s Post

This is not only a real breakthrough in plasma collection efficiency. With the FDA granting 510(k) clearance to Fresenius Kabi’s Adaptive Nomogram, we are further strengthening our commitment to the U.S. healthcare market and to improving access to life-saving therapies for U.S. patients. This innovation will help enable plasma centers to deliver more state-of-the-art therapies to patients in need. Plasma-derived therapies have major potential and are essential to treating various conditions, from immune deficiencies to neurological diseases. Great work, #TeamFresenius! This is #CommittedToLife at its best! #FutureFresenius

Proteomics International has topped up its coffers with a $2.16m R&D tax incentive boost that will help kick-off the commercial launch of three potentially ground-breaking, simple diagnostic blood tests. $PIQ #ProMarkerD #BULLSNBEARSWA The Sydney Morning Herald

Continuing the walk through our history of innovation, we would like to stop in 1965, when Víctor Grifols i Lucas developed a new plasmapheresis centrifuge that made the plasma donation process more efficient and safer. In its early days, technical limitations meant that plasmapheresis was not as safe as it is today. The time needed to centrifuge the donation of whole blood was five or six hours, due in part to the centrifuging process being separate from the extraction process. This new centrifuge allowed plasmapheresis to be performed right next to the donor, and cells and platelets could be reinfused immediately after extraction. For the first time the three steps were efficiently integrated into one seamless process. The process allowed donors to donate more frequently, resulting in a wider and safer supply for plasma-derived medicines. Dive deep into our legacy of innovation 👉 http://spr.ly/6049SKa1x #Since1909

Proteomics International has topped up its coffers with a $2.16m R&D tax incentive boost that will help kick-off the commercial launch of three potentially ground-breaking, simple diagnostic blood tests. $PIQ #ProMarkerD #BULLSNBEARSWA The Sydney Morning Herald https://lnkd.in/gNRDtgmS

Earlier this year, we announced the publication of our CLEANVLU Phase IIa clinical trial report in the International Wound Journal. The study compared five escalating dose concentrations of tarumase for enzymatic debridement and wound bed preparation against baseline.   ➡️Established proof-of-concept that tarumase successfully debrides wounds, with faster and more complete debridement and improved healing observed at increased enzyme concentrations. ➡️Demonstrated a strong safety profile, with no indications of systemic absorption, antibody generation, or systemic effects on coagulation. ➡️Found that the application of Aurase Wound Gel was pain-free, did not add to patients’ existing pain burden, and presented no evidence of local tolerability issues.   As the year draws to a close, it is great to see our publication in the top 5% of all research outputs (as tracked by Altmetric) —an encouraging testament to the clinical interest in the need to achieve effective wound debridement with Aurase Wound Gel as alternative means to achieve wound bed preparation. #WoundCare #ChronicWounds #ClinicalTrial

OnkoSight NGS results in as fast as 3 days! How long are you waiting for results? #oncology #NGS #cancer #pathology #molecular #hematology #cancerdiagnostics

The number of patients who need plasma-derived medicines (PDMPs) has risen in recent years. Advances in medical diagnostics have led to more precise and earlier diagnoses. More people are benefiting from these treatments and living longer. There is also growing clinical evidence of the benefits of PDMPs for patients. This #IPAW2024, we invite you to visit www.plasmaweek.org and join us in advocating for more plasma donations, improved supply chains, and patient-centric policies that support greater strategic autonomy for Europe to manufacture PDMPs and to meeting growing patient need for PDMPs. #IVIG #GBS #CIDP

https://lnkd.in/eMR8YV74 Incredible paper - thank you to the authors who published this. I still find it challenging determining the optimal use of adjuvant pembro in TNBC. What do you do in your practice?

🌟 May 16th is hae day :-) Hereditary Angioedema 🌟 📅 Today, let's reflect on the incredible strides we've made in advocating for better therapies and an improved quality of life for those affected by Hereditary Angioedema. 🚀 I'm thrilled to share that we are currently witnessing an unprecedented number of effective therapies, with eight FDA-approved products already available and an impressive thirteen more in development. This progress is a testament to the dedication and hard work of countless researchers, clinical teams, and advocates in our community. As we continue to build momentum, let's harness the galvanizing force of HAE Day to fuel the ongoing quest for new and improved treatments. 🙏 A huge thank you to all the researchers and clinical teams who tirelessly dedicate themselves to advancing HAE treatment options. Your efforts are truly changing lives. Let's keep pushing forward! #haeday #HAEawareness #citeline Astria Therapeutics, Inc. Hereditary Angioedema Association - HAEA #clinicalresearch #clinicaltrials #clinicaldevelopment

New in #chronicmyeloidleukemia management on #Heme Today: A phase II trial led by Elias Jabbour, MD, of MD Anderson Cancer Center found #dasatinib plus #venetoclax to be effective and safe for chronic phase #CML https://lnkd.in/eKPiSkq3